Home

EDV
EDV
EDVs
The EDV nanocell is a first-in-class cyto-immunotherapy platform targeting the tumor directly and leveraging the patient’s own immune system.
Covid EDV
We need healthy heroes to volunteer for our therapeutic vaccine trial against COVID 19

You will be:
* 18 years old or older
* In good health
* Helping vulnerable patients with pre-existing conditions who may not respond well to COVID vaccines

For more information please contact St Vincent's Hospital Melbourne (SVHM)
Department of Gastroenterology
Clinical Trials Teams 03 9231 3580

For more information

COVID-EDV ENG12 Master Volunteer Flyer v2.0 dated 5Jul2021
SVHM Volunteer Flyer v1.0 dated 0Jul2021

MORE INFO
previous arrowprevious arrow
next arrownext arrow
Shadow

 

Breaking News

EnGeneIC develops world-first nanocellular anti-COVID-19 vaccine that defeats mutant viruses and stimulates a broad anti-viral response

 

Click for full story

 

 

  • Works against mutant strains including Delta

  • No need for refrigeration during transport and storage

  • No added stabilisers or chemicals

  • Safety and immune response clinical trial recruiting now in Melbourne

  • Efficacy trial planned for USA.

For more information about becoming a volunteer for the COVID-19 EDV™ Vaccine Trial contact:

Despina Anagnostou - St Vincents Hospital Melbourne

+61 3 9231 3490         Despina.Anagnostou@svha.org.au

 

Learn more about EnGeneIC Dream Vector (EDV™) Nanocell platform technology

Publication in prestigious scientific journal, Cancer Cell, highlighting the ability of EDV™ Nanocells to mount dual assault on Cancer Cells

EDV™ Technology Stimulates Both Innate and Adaptive Immune Response and Confers Long-Term Survival

Abstract accepted  to the Annual Meeting of the American Society of Clinical Oncology 2020

Abstract Demonstrates Promising Early Results from Phase I/IIa study in Patients with Recurrent, Metastatic Pancreatic Cancer.